About Us
ABOUT US
Pharma grade analytics
Multi-omics, single-cell, spatial — without the analytics bottleneck.
MiraOmics turns single-cell, spatial, and multi-omic data into decisions pharma and biotech teams can act on: a biomarker, a translational readout, a clear view of where to invest next.
Where MiraOmics Fits
MiraOmics is a specialized boutique for early discovery, translational, and reverse translational work, built specifically around multi-omics, single-cell, and spatial data. That means senior expertise applied directly to your problem, fast turnaround, and methods your team can keep afterward.
Hiring a MiraOmics fills the gap between bringing on a Head of Bioinformatics — where you own the process but wait six to eight months for full productivity — and a large CRO, which brings scale and governance but is often slow and costly for a focused problem. For a specific, well-defined questions, it’s usually the fastest path to an answer.
MiraTyper — our batch-resistant, state of the art, pan-organ cell-type classification platform, built and trained in-house. Point it at your dataset and it harmonizes cell types in a fraction of the time manual annotation takes.
Pythiomics data access — through a data partnership with Pythia Biosciences, we draw on one of the largest curated multi-omics databases available: 233M+ cell profiles as of August 2026, growing by tens of millions a month, across oncology, neurology, cardiovascular disease, hematology, and more. Standardized, harmonized, fully traceable — and the foundation MiraTyper was trained on.
Why MiraOmics?
A Series A biotech and a top-20 pharma R&D group don’t share a budget or a risk tolerance, so we don’t start from a template. We build around your program, your data, and your goals. That’s the idea behind the name: MiraOmics exists to accelerate the path from multi-omic data to something you can act on.
How We Deliver Results
- Start with the right question — not “what’s in this data” but “does TCR clonal dominance predict CRS severity?”
- Plan before touching the data — methods, data needs, and failure modes, defined before analysis starts.
- Break it into sub-questions — each one precise enough to answer on its own.
- Draw on Pythiomics and MiraTyper — instead of starting from zero, we can deliver results even if you have no data, or put your data in to context.
- Fix deliverables and timelines up front — analysis plan by week 1, report by week 2, metadata by day 5.
- Deliver outputs built for what’s next — figures, regulatory tables, data objects, reproducible code.
Our Clients
Discovery and translational biologists. Multi-omic data is expensive to generate, and budgets rarely stretch as far as the science demands. We use Pythiomics and MiraTyper to extract more signal from fewer samples, so target validation and patient stratification don’t wait on a bigger budget.
Bioinformatics and computational biology teams. A pipeline that survives regulatory scrutiny and gets adopted by bench scientists is a different build than a one-off script. We’ve shipped NGS, single-cell, and spatial pipelines — including ones behind FDA submissions — that integrate with your legacy data instead of replacing it.
Pharma and biotech business leaders. Performing due dillgence on a multi-omics platform or an acquisition target usually means a technical call your team isn’t fully staffed to make alone. We help you reach a clear, defensible view fast enough to keep the deal moving.
Leadership team:
Eugene Bolotin, Co-Founder and CEO
Eugene Bolotin, Ph.D., brings over 12 years of experience in bioinformatics, genomics, and data science to his role as Co-Founder and CEO of MiraOmics. He is responsible for the company’s scientific direction and strategy, translating multi-omic data into decisions for pharmaceutical and biotechnology partners.
Prior to founding MiraOmics, Eugene was Head of Bioinformatics at Santa Ana Bio, where he built the data platform team from the ground up and was instrumental in raising $168M across Series A and B funding rounds from investors including Google Ventures, Versant Ventures, TPG, and Andreessen Horowitz. Earlier in his career, Eugene held bioinformatics leadership roles at Kite Pharma (a Gilead company), Cell Design Labs, and Illumina.
Eugene is a specialist in target and biomarker discovery, patient stratification, synthetic biology, and genomic and analytics software development, with experience spanning bench-level genomics to executive leadership across the pharmaceutical, biotechnology, and genomics industries.
A proven leader, Eugene has a track record of building bioinformatics organizations from the ground up, including as a founding member of the bioinformatics department at Cell Design Labs, which was acquired by Kite/Gilead for $567M within two years. His work has contributed to two FDA-cleared IND applications and to publications cited more than 1,000 times. Eugene holds a Ph.D. in Genetics, Genomics, and Bioinformatics from the University of California, Riverside.
RJ Honicky Co-Founder and CTO
RJ Honicky brings over 20 years of experience in engineering and technology to his role as CTO at MiraOmics. He is responsible for building the engineering and data science capabilities behind MiraOmics’ analytics and AI/ML platform.
Prior to joining MiraOmics, RJ was Director of Engineering at Tarana Wireless, overseeing AI/ML, data science, and manufacturing test systems. Earlier in his career, RJ held senior technical and research positions at Nokia Research and Network Appliance.
RJ is a specialist in AI/ML, data infrastructure, and full-stack systems engineering, with experience spanning board- and rack-level hardware to web-scale data systems across telecommunications, mobile computing, and enterprise storage.
A proven engineering leader, RJ has a track record of building high-performing teams from the ground up. His leadership has driven measurable results, including an 84% reduction in mean outage time across a fleet of 140,000 connected devices. RJ holds a PhD in Computer Science from UC Berkeley and an MS in Computer Science from UC Santa Cruz.
Serge Bery, Chief Security Information Officer (CISO)
Serge Bery brings over 29 years of experience in the technology sector to his role as Chief Information Security Officer (CISO) at Miraomics .bio. He is responsible for tackling evolving security challenges that require balancing technology, business priorities, and human nature. Prior to joining Miraomics .bio, Serge was Head of Security at Hewlett-Packard and Micro Focus, overseeing the information and operational technology security strategy and governance. Earlier in his career, Serge held senior leadership positions at several other organizations, including Smarsh, Microsoft, Aircell, and Allscripts.
Serge is a specialist in information and cyber security, cloud services, enterprise risk, technology risk, and business resilience, with experience spanning in-depth engineering to board-level management across multiple industries and geographies.
A proven leader, Serge has a track record of guiding teams to success. His leadership skills have been instrumental in driving security initiatives and fostering a culture of security awareness within organizations. Serge holds industry-leading certifications, including ISACA CISM and CISA.
List of services
MiraOmics offers analytics and advisory services across the full arc of drug development — from target discovery and validation through multi-omics, to clinical and translational biomarker pipelines, manufacturing analytics for cell therapy, spatial transcriptomics, and single-cell integration, all built on the same infrastructure behind MiraTyper. We also advise pharma and biotech leaders and investors directly, on analytics strategy, team building, and technology due diligence, through engagements ranging from a free 30-minute consult to long-term strategic partnerships.
Our affiliates
